ReviewCurrent opinion in gastroenterology2017
Novel insights into microbiome in colitis and colorectal cancer.
Review in Current opinion in gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Predicting Personalized Diets Based on Microbial Characteristics between Patients with Superficial Gastritis and Atrophic Gastritis.Nutrients · 2023Pooled it
- Cholecystectomy promotes the development of colorectal cancer by the alternation of bile acid metabolism and the gut microbiota.Frontiers in medicine · 2022Pooled it
- Effect of Garambullo (International journal of molecular sciences · 2026Article
- Article
- Phloretin-induced modulation in gut microbiome, mitigates colonic inflammation and alleviates colitis-associated colorectal cancer in mice.Computational and structural biotechnology journal · 2025Article
- Microbiome-microRNA interactions in inflammatory bowel disease: insights from metagenomic and transcriptomic data analysis.Gastroenterology and hepatology from bed to bench · 2025Article
- MicroHDF: predicting host phenotypes with metagenomic data using a deep forest-based framework.Briefings in bioinformatics · 2024Article
- Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune Responses for Potentiated Colorectal Cancer Treatment.Research (Washington, D.C.) · 2024Article
- Characteristics of stachyose-induced effects on gut microbiota and microbial metabolitesFrontiers in nutrition · 2024Article
- The oral bacterial microbiota facilitates the stratification for ulcerative colitis patients with oral ulcers.Annals of clinical microbiology and antimicrobials · 2023Article
- Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease.Molecular neurodegeneration · 2023Article
- Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future.International journal of molecular sciences · 2023Review
- Korean Red Ginseng extract treatment prevents post-antibiotic dysbiosis-induced bone loss in mice.Journal of ginseng research · 2023Article
- The Gut Microbiome and Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2023Article
- New insights into the interplay between intestinal flora and bile acids in inflammatory bowel disease.World journal of clinical cases · 2022Review
- The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments.Journal of microbiology and biotechnology · 2022Review
- The Many Ages of Microbiome-Gut-Brain Axis.Nutrients · 2022Article
- Review
- The effects of the oral administration of graphene oxide on the gut microbiota and ultrastructure of the colon of mice.Annals of translational medicine · 2022Article
- Quercetin positively affects gene expression profiles and metabolic pathway of antibiotic-treated mouse gut microbiota.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewMicrobiota is a major player in the pathogenesis of inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Here, we summarize the key advances achieved in the past 18 months (ending June 2017) toward a better understanding of the role of microbiota in colitis and CRC development. RECENT
findingsAccumulating evidence shows the essential role of intestinal barrier function (e.g. mucus, IgA, LCN2, LYPD8) in protecting against bacteria-induced inflammation and tumor development. Numerous signaling pathways (e.g. TLRs and NLRs), metabolites (e.g. indole, bile acids, retinoic acid) and small noncoding RNAs (e.g. miRNA) have been identified as key mediators regulating host-microbe interactions in the intestine. Novel microbial drivers of colitis and tumorigenesis (e.g. Alistipes finegoldii, Atopobium parvalum, Peptostreptococcus anaerobius) have been identified and their disease-promoting activities have been described. SUMMARY: IBD-associated colorectal cancer results from a complex breakdown of communication between the host and its microbiota, involving barrier function, immune signaling and metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.